CSIMarket


Mediwound Ltd   (MDWD)
Other Ticker:  
 


 

Mediwound Ltd

MDWD's Financial Statements and Analysis



Mediwound Ltd reported break-even for the forth quarter of 2023 compare to net loss per share of $-0.34 recorded in the same quarter a year ago an improvement compare to $0.00 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ 0 $  0 Mill
$+0.34     $-22M    



Mediwound Ltd 's Revenue fell by 0 % in forth quarter of 2023 (Dec 31 2023) year on year, to $0 million and declined by sequentially.


Mediwound Ltd is

More on MDWD's Income Statement



Mediwound Ltd in the forth quarter of 2023 recorded net loss of $0.000 million, an improvement compare to net loss of $-9.196 million in IV. Quarter a year ago.

Sequentially net loss narrowed from net loss of $0.000 million realized in previous quarter.

More on MDWD's Growth

Mediwound Ltd Inventories
MDWD's Cash flow In the forth quarter of 2023 company's net cash flow was $34 million, capital expenditures fell by -0.923600.33%, to $-6 millions compare to same quarter a year ago

More on MDWD's Cash flow Statement


Mediwound Ltd






More on MDWD's Dividends

 Market Capitalization (Millions) -
 Shares Outstanding (Millions) -
 Total Debt (Millions $) 2
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 34
 Capital Exp. (TTM) (Millions $) -6
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Mediwound Ltd






More on MDWD's Balance Sheets

 Market Capitalization (Millions) -
 Shares Outstanding (Millions) -
 Total Debt (Millions $) 2
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 34
 Capital Exp. (TTM) (Millions $) -6
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Mediwound Ltd Earnings

Legal Cannabis Industry Holds Steady Revenue in Fourth Quarter of 2023 Amidst Changing Market Trends

Mediwound Ltd, a leading innovator in burn and wound care treatments, has experienced a decline of 10.77% in its shares during March 2024, which brings the share price to 39.82% for the first quarter of 2024. Despite this decline, the shares are trending higher and are just 8.8% short of reaching its 52-week high.
The company's financial results for 2023 indicate that it generated $19 million in revenue, and it has projected revenue of $24 million for 2024. Furthermore, Mediwound successfully launched its product called NexoBrid in the United States, Japan, and India. This achievement is a significant milestone for the company, as NexoBrid aims to offer a non-surgical solution for pediatric patients in t...